Global Nasopharyngeal Cancer Market Size (2024 - 2029)

The nasopharyngeal cancer market is projected to experience growth over the forecast period, driven by an increase in cancer cases and heightened awareness of treatment and diagnosis options. The market's expansion is expected to recover from the impacts of the COVID-19 pandemic, which had previously delayed diagnoses and treatments, thereby affecting market demand. Despite challenges such as high treatment costs and adverse side effects, the market is anticipated to benefit from ongoing research and development activities, strategic partnerships, and new product approvals. These factors collectively contribute to the anticipated growth in market size.

Market Size of Global Nasopharyngeal Cancer Industry

Nasopharyngeal Cancer Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
CAGR 2.70 %
Fastest Growing Market Asia-Pacific
Largest Market North America
Market Concentration Medium

Major Players

Nasopharyngeal Cancer Market  Major Players

*Disclaimer: Major Players sorted in no particular order

Nasopharyngeal Cancer Market Analysis

Over the next few years, the market for nasopharyngeal cancer is expected to grow at a CAGR of 2.7%.

The COVID-19 pandemic impacted the global nasopharyngeal cancer (NPC) market. For instance, a November 2021 article by NCBI stated that the COVID-19 period saw a delay in the diagnosis of head and neck malignancies in comparison to the pre-COVID-19 period.Thus, the decrease in diagnosis of such patients reduced the number of surgeries and treatments, thereby affecting the market demand for the therapies among the end users. However, in the current scenario, it was expected that with the decreasing COVID-19 cases and the reopening of surgical and diagnosis centers globally, the market would witness significant growth over the forecast period.

The growth of the studied market is being fueled by the increasing number of cases of nasopharyngeal cancer and the growing awareness of treatment and diagnosis among the general public. Both of these things are expected to keep the market growing.

The American Cancer Society's revised data, released in August 2022, reported that throughout life, the risk of NPC increases slowly, but people of any age get the disease, including children. In places with a high risk of NPC, like China, people are often diagnosed between 45 and 59 years old, when they are at their peak. In places with a low risk of NPC, like the United States, cases are more common in young adults (15 to 24 years old), then drop until another peak between 65 and 79 years old.

Also, the source mentioned above says that NPC is much more common in some parts of South Asia, the Middle East, and North Africa.Native Americans in the Arctic also experience it more frequently. Additionally, the World Cancer Research Fund International (WCRF) data updated in 2022 shows that NPC is the 22nd most prevalent cancer in the world, and in terms of prevalence, it ranks 22nd among cancers in women and 18th among cancers in men. As per the WCRF, around 133,000 new NPC cases were diagnosed globally in 2020. Thus, to coordinate with the disease burden, the government and major companies are focusing more on developing therapies and drugs. This is anticipated to drive market growth.

During the analysis period, the market also grew because there were more research and development (R&D) activities, collaborations, strategic partnerships, product approvals, and product launches.For instance, the Food and Drug Administration (FDA) accepted a biologics license application (BLA) in July 2022 for toripalimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced recurrent or metastatic nasopharyngeal carcinoma.The BLA will be reviewed over the next 6 months, with a prescription drug user-free act date of December 23, 2022, and a launch in the first quarter of 2023 after the approval. Thus, such developments in the market are anticipated to fuel market growth.

So, the studied market is likely to grow because there are more cases of nasopharyngeal cancer and more people are becoming aware of how to treat and diagnose the disease. But the high costs and bad side effects of the treatments are likely to slow the growth of the market over the next few years.

Nasopharyngeal Cancer Industry Segmentation

As per the scope of the report, nasopharyngeal cancer is a disease in which cancer cells form in the tissues of the nasopharynx (the upper part of the throat behind the nose). The risk of nasopharyngeal cancer can be affected by many things, including one's race and whether or not they have been exposed to the Epstein-Barr virus. Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, and Others), End User (Hospitals and Clinics, Ambulatory Surgery Centers, and Other End Users), and Geography (North America, Europe, Asia-Pacific, the Middle East and Africa, and South America) are the segments of the Nasopharyngeal Cancer Market. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Therapy
Chemotherapy
Immunotherapy
Radiation Therapy
Other Therapies
By End-Users
Hospitals and Clinics
Ambulatory Surgery Centers
Other End-Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Nasopharyngeal Cancer Market Size Summary

The nasopharyngeal cancer market is poised for growth, driven by an increasing incidence of the disease and heightened awareness of treatment and diagnosis options. The market experienced disruptions due to the COVID-19 pandemic, which delayed diagnoses and treatments, but is expected to recover as surgical and diagnostic centers reopen globally. The prevalence of nasopharyngeal cancer varies by region, with higher rates observed in areas such as China, South Asia, and the Middle East. This geographical disparity has prompted governments and pharmaceutical companies to focus on developing effective therapies, thereby stimulating market expansion. The market's growth is further supported by ongoing research and development activities, strategic partnerships, and regulatory approvals for new treatments, such as the FDA's acceptance of a biologics license application for toripalimab in combination with chemotherapy.

North America is anticipated to witness significant market growth due to the rising prevalence of nasopharyngeal cancer and the presence of key market players driving technological advancements and product innovations. The demand for nasopharyngeal cancer drugs is increasing, particularly in Canada and Mexico, where case numbers have risen over the past decade. Regulatory approvals for new drugs and ongoing clinical studies are expected to further accelerate market growth in the region. Despite the limited number of companies in the market, major global and regional players hold substantial market shares. Initiatives such as cancer screening programs and clinical trials for novel treatments are contributing to the market's development, indicating a positive outlook for the nasopharyngeal cancer market over the forecast period.

Explore More

Global Nasopharyngeal Cancer Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Burden of the Cancer Disease

      2. 1.2.2 Growing Awareness Towards Diagnosis and Treatment

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of the Treatment

    4. 1.4 Porter's Five Forces Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Therapy

      1. 2.1.1 Chemotherapy

      2. 2.1.2 Immunotherapy

      3. 2.1.3 Radiation Therapy

      4. 2.1.4 Other Therapies

    2. 2.2 By End-Users

      1. 2.2.1 Hospitals and Clinics

      2. 2.2.2 Ambulatory Surgery Centers

      3. 2.2.3 Other End-Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Nasopharyngeal Cancer Market Size FAQs

The Global Nasopharyngeal Cancer Market is projected to register a CAGR of 2.70% during the forecast period (2024-2029)

Bristol Myers Squibb, Eli Lilly and Company, Merck & Co., Inc., Novartis AG and GlaxoSmithKline (GSK) PLC are the major companies operating in the Global Nasopharyngeal Cancer Market.

Nasopharyngeal Cancer Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)